Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Medrx shares plunge after schizophrenia drug trial fails to meet primary endpoint
Medrx Co.,Ltd. <4586> shares fell sharply. The company announced earlier in the day topline results from a Phase 2 clinical trial of Alto-101, a schizophrenia treatment drug (PDE4 inhibitor patch) being developed in partnership with U.S. biopharmaceutical venture Alto Neuroscience
Source: MINKABU PRESS
Related Articles
KANSAI PAINT gains further in afternoon trading after Silchester's over 5% stake revealed
NIPPON FILCON hits new year-to-date high in afternoon trading on return to operating profit in Dec-Feb quarter
QPSHD Surges in Afternoon Session on News of Winning Contract for Small SAR Satellite Constellation Demonstration Project
GENOVA rises for third consecutive day on subsidiary acquisition of dental materials supplier Akasaka Dental Materials
Towns <197A.T> Ranks Third in Rising Sell Predictions Among Individual Investors
Yushin Company continues to rise on planned gain from sale of investment securities for fiscal year ending March 2026
Chiyoda shares surge as Golden Pass LNG Project's Train 1 construction and commissioning completed in U.S.
FTGroup shares decline on share exchange ratio with HIKARI TSUSHIN
Columbia Works rises for first time in three days on construction start of hotel development project on Kouri Island, Okinawa
Olympic Group hits daily limit up on monthly magazine report sparking speculation